Real-world dosing of adalimumab and secukinumab in hidradenitis suppurativa: Updated biologic treatment pattern analysis
SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s867
DOI: 10.25251/7vhevw90 ↗Abstract
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful lesions mainly at flexural sites. Real-world data help with understanding dosing patterns for biologics such as adalimumab (ADA) and secukinumab (SEC) in clinical practice. United States (US) Food and Drug Administration (FDA)-recommended dosing in adults with moderate-to-severe HS: ADA: 160mg initial dose; Day 15: 80mg; from Day 29: 40mg weekly or 80mg every 2 weeks (Q2W). SEC: 300mg initial dose at Weeks 0, 1, 2, 3, 4; and every 4 weeks (or Q2W if inadequate response) thereafter. This analysis adds 1 year (y) of US claims data to a previously presented study of real-world dosing patterns in an HS cohort. Procedure/Study: Eligible patients had at least one ADA or SEC claim with an HS diagnosis code during April 2017–September 2025, and continuous benefits enrollment spanning 3 months (m) before and after earliest biologic therapy claim. Dosing patterns were reported by initial (index) dose and highest average daily dose observed each month, in enrolled patients receiving ADA or SEC, as weekly dose categories based on label information. Anticipated ADA index and maintenance doses: 60 and 40mg/week, respectively; SEC: 300 and 75–150mg/week. Continuous variables reported as means (standard deviation [SD]); categorical: n (%). Results: Among 6,487 eligible patients, mean (SD) age was 40.8 (13.9) years. Majority (4,809 [74.1%]) were female; 3,438 (53.0%) non-Hispanic white; 1,468 (22.6%) non-Hispanic Black; 5,013 (77.3%) had commercial health insurance. At index, 4,623 (71.3%) and 1,864 (28.7%) patients received ADA and SEC, respectively. Among ADA recipients, 3,643 (78.8%) received 60mg/week at index, 40mg/week: 518 (11.2%), and 20mg/week: 392 (8.5%). Patients continuously enrolled with a nonzero dose receiving ADA 60, 40, 20mg/week, or other weekly dosing, respectively: at 6m: 7 (0.24%), 2,605 (87.7%), 341 (11.5%), and 16 (0.54%); at 1y: 7 (0.41%), 1,507 (88.3%), 176 (10.3%), and 17 (1.0%). At 6m and 1y, respectively, 72.5% and 54.0% of continuously enrolled patients still received ADA. For SEC at index, 1,015 (54.4%) patients received 600mg/week, 300mg/week: 455 (24.4%), 150mg/week: 264 (14.2%), and 75mg/week: 97 (5.2%). Patients continuously enrolled with a nonzero dose receiving SEC 600, 300, 150, 75mg/week, or other weekly dosing, respectively: At 6m: 3 (0.3%), 147 (13.0%), 662 (58.6%), 283 (25.0%), and 35 (3.1%); at 1y: 2 (0.4%), 120 (22.5%), 275 (51.5%), 125 (23.4%), and 12 (2.3%). At 6m and 1y, respectively, 74.0% and 53.0% of continuously enrolled patients still received SEC. Conclusion: Approximately half of continuously enrolled patients receiving ADA or SEC at index continued to receive them at 1y. Among those continuously enrolled, ADA dosing generally aligned with label guidance. However, more than half of patients on SEC received a higher than recommended index dose, and almost three quarters were receiving ≥150mg/week at 1y. These findings underscore unmet needs and dosing variability with SEC in HS management, with many patients requiring higher-than-recommended maintenance doses.
EUVIMED